Peptide - Articles - Page 5

Endocrine/metabolic

Pep2tango Therapeutics advances tetra-agonists for obesity

Nov. 22, 2024

Startup company Pep2tango Therapeutics Inc., unveiled with backing by Versant Ventures, is advancing unimolecular multireceptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors.

Dermatologic

Protagonist Therapeutics selects IL-17 antagonist as development candidate

Nov. 22, 2024

Protagonist Therapeutics Inc. has selected PN-881, an oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases.

Drug design, drug delivery & technologies

Aizen Therapeutics emerges from stealth to develop full D-amino acid therapeutics

Nov. 21, 2024

Aizen Therapeutics has emerged from stealth with a focus on early-stage programs powered by its novel drug discovery platform, Dax.

3D rendering conceptualizing theranostics

Cancer

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors

Nov. 14, 2024

Artbio Inc. and 3B Pharmaceuticals GmbH have signed a worldwide, exclusive license and research agreement to develop an advanced preclinical stage first-in-class peptide α-radioligand therapy for the treatment of solid tumors.

Endocrine/metabolic

Adipopharma raises funding for phase I trials of PATAS for type 2 diabetes

Nov. 12, 2024

Adipopharma SAS has secured funding to begin phase I trials of PATAS, a compound with a novel mechanism for treating type 2 diabetes.

Cancer

AVA-6103 for the treatment of FAP-positive cancer by targeting topoisomerase

Nov. 6, 2024

Avacta Life Sciences (Avacta Group plc) presented preclinical data on AVA-6103, a second-generation Precision peptide-drug conjugate, being developed for the potential treatment of cancer. AVA-6103 was developed using the company’s proprietary Precision technology incorporating a dipeptide specifically cleaved by fibroblast activation protein α (FAPα) leading to tumor-specific delivery of exatecan directly into the tumor cells.

Endocrine/metabolic

Endevica Bio spins off Abisati to develop oral MC4 receptor agonist for weight loss

Nov. 4, 2024

Endevica Bio Inc. has announced the spin-off of a newly created company, Abisati LLC, to develop an oral melanocortin MC4 receptor agonist, 710GO, as a weight loss therapy.

Ocular

QM-107, a novel therapeutic peptide for the treatment of neovascular eye diseases

Oct. 25, 2024

Syndecan-2 can inhibit angiogenesis through its interaction with the protein tyrosine phosphatase receptor CD148 (RTP type J).

Neurology/psychiatric

Fu Jen Catholic University develops new peptides for treatment of ALS

Oct. 22, 2024

Fu Jen Catholic University has created peptides for use in the treatment of amyotrophic lateral sclerosis (ALS).

Microscope with laptop displaying histology image.

Cancer

Avacta adds new preclinical oncology assets to pipeline

Oct. 17, 2024

Avacta Group plc has expanded its pipeline of Precision-enabled drug conjugates with the addition of two novel preclinical oncology assets, AVA-6103 and AVA-7100. The company’s peptide-drug conjugates (PDCs) comprise a payload linked to the Precision peptide, which is cleaved only within the tumor by the action of fibroblast activation protein (FAP).

Peptide, BioWorld Science
RSS

Pep2tango Therapeutics advances tetra-agonists for obesity

Protagonist Therapeutics selects IL-17 antagonist as development candidate

Aizen Therapeutics emerges from stealth to develop full D-amino acid therapeutics

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors

Adipopharma raises funding for phase I trials of PATAS for type 2 diabetes

AVA-6103 for the treatment of FAP-positive cancer by targeting topoisomerase

Endevica Bio spins off Abisati to develop oral MC4 receptor agonist for weight loss

QM-107, a novel therapeutic peptide for the treatment of neovascular eye diseases

Fu Jen Catholic University develops new peptides for treatment of ALS

Avacta adds new preclinical oncology assets to pipeline

Today's news in brief

Today's news in brief

ADCs’ breakout 2025 and their still-unfinished potential

LINC01116 has prognostic value in lung cancer, study shows

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

Peptide, BioWorld Science RSS

Peptide, BioWorld Science
RSS